# Problem Statement — P1
## IBM BoB AI Innovation Hackathon 2026 | ClinicalAI Monitor | Team Hackaholics

---

## Background

Clinical trials are the cornerstone of modern drug and medical device development. Every trial operates under a strict **protocol** — a legally binding document that specifies exactly how the trial must be conducted: patient visit schedules, dosing regimens, permitted and banned co-medications, required laboratory tests, and documentation procedures. These protocols are governed by the **ICH E6 Good Clinical Practice (GCP)** guidelines, enforced by the FDA (21 CFR Part 312) and the EMA.

A typical Phase III trial involves **5,000+ patient visits** across **200+ research sites** worldwide, spanning 2–5 years. Managing compliance at this scale is an enormous operational challenge.

---

## The Problem

**42% of clinical trial sites have unreported protocol deviations** (industry benchmark). The root cause is the manual monitoring model:

- Clinical Research Associates (CRAs) conduct **periodic site visits** — typically every 6–12 weeks
- By the time a deviation is discovered, it may have occurred weeks earlier and impacted patient safety
- Manual classification of deviations is **inconsistent** across sites and monitors
- CAPA (Corrective and Preventive Action) reports take **2–3 days** to prepare per site
- There is **no aggregated, real-time view** of which sites carry the highest compliance risk
- Deviations are often discovered only during the **FDA audit** — far too late to correct

Specific deviation types that go undetected include:
- **Missed visits** — patient did not attend within the ±7-day protocol window
- **Late visits** — visit occurred more than 7 days outside the scheduled date
- **Wrong dose** — investigational product administered at incorrect dose (e.g., 2× or 0.5× expected)
- **Banned co-medications** — patient is taking a protocol-prohibited drug (e.g., Warfarin, Methotrexate)
- **Missing laboratory tests** — required protocol lab not completed at the visit
- **Incomplete documentation** — consent forms or eCRF entries missing or unsigned

---

## Who is Affected

- **Risk Managers and Clinical Operations Leads** — need real-time site risk visibility before FDA audits
- **Clinical Research Associates (CRAs)** — spend 70%+ of their time on manual record review
- **Principal Investigators (PIs)** — face criminal liability for systematic protocol violations
- **Sponsors (pharmaceutical companies)** — bear the $50–100M cost of delayed drug approvals
- **Patients** — receive substandard care when protocol violations go undetected

---

## Why It Matters

A single FDA audit finding that rejects data from non-compliant sites can:
- **Delay drug approval by 6–12 months** — costing $50–100M in revenue
- **Trigger a Clinical Hold** — halting the entire trial
- **Result in $250,000+ fines** per violation
- **Expose Principal Investigators** to personal criminal liability
- **Delay life-saving treatments** from reaching patients

The 2021 Theranos case and multiple high-profile FDA warning letters demonstrate the catastrophic consequences of inadequate clinical trial oversight.

---

## Why Existing Solutions Fall Short

Current solutions (Medidata Rave, Oracle Clinical One, Veeva Vault) are **data capture systems**, not intelligence systems:

| Existing Approach | Gap |
|---|---|
| Manual CRA site visits every 6–12 weeks | Deviations found weeks after occurrence — too late |
| EDC (electronic data capture) systems | Capture data but do not analyse it for deviations |
| Periodic monitoring reports | Backwards-looking, narrative format, inconsistent |
| Manual CAPA creation | 2–3 days per report, subjective quality |
| No site risk aggregation | Audit surprises — no leading indicators |

**What is needed:** A real-time, AI-powered system that continuously compares patient records against the protocol specification, classifies every deviation the moment it occurs, and gives risk managers a live, ranked view of site risk — enabling proactive intervention before FDA audits.
